Equities analysts expect ResMed Inc. (NYSE:RMD) to post earnings of $0.76 per share for the current quarter, according to Zacks. Two analysts have made estimates for ResMed’s earnings. The lowest EPS estimate is $0.72 and the highest is $0.81. ResMed reported earnings of $0.73 per share during the same quarter last year, which would indicate a positive year over year growth rate of 4.1%. The firm is expected to report its next earnings report on Monday, January 22nd.
According to Zacks, analysts expect that ResMed will report full-year earnings of $3.00 per share for the current financial year, with EPS estimates ranging from $2.87 to $3.16. For the next year, analysts expect that the firm will post earnings of $3.35 per share, with EPS estimates ranging from $3.18 to $3.71. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover ResMed.
ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting analysts’ consensus estimates of $0.66. The firm had revenue of $523.66 million for the quarter, compared to analysts’ expectations of $506.08 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 EPS.
Several research firms recently issued reports on RMD. Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a research report on Tuesday, August 8th. Zacks Investment Research cut ResMed from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Northland Securities reaffirmed a “sell” rating and issued a $55.00 price objective on shares of ResMed in a research report on Friday, October 27th. Jefferies Group LLC reaffirmed a “sell” rating and issued a $56.00 price objective on shares of ResMed in a research report on Thursday, October 12th. Finally, BMO Capital Markets upped their price objective on ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research report on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $67.57.
ResMed (NYSE RMD) traded up $0.01 during mid-day trading on Monday, reaching $84.64. The company had a trading volume of 162,365 shares, compared to its average volume of 867,633. The company has a market cap of $12,009.33, a PE ratio of 29.49, a PEG ratio of 1.88 and a beta of 0.79. ResMed has a fifty-two week low of $57.45 and a fifty-two week high of $87.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be issued a dividend of $0.35 per share. The ex-dividend date is Wednesday, November 8th. This represents a $1.40 annualized dividend and a dividend yield of 1.65%. ResMed’s payout ratio is 56.68%.
In other news, Director Peter C. Farrell sold 118,392 shares of the company’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $82.70, for a total value of $9,791,018.40. Following the completion of the sale, the director now directly owns 306,615 shares in the company, valued at approximately $25,357,060.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $77.56, for a total value of $96,950.00. Following the completion of the sale, the chief financial officer now owns 65,941 shares of the company’s stock, valued at $5,114,383.96. The disclosure for this sale can be found here. Insiders sold a total of 201,234 shares of company stock valued at $16,339,637 over the last 90 days. 1.77% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of the business. Crestwood Advisors Group LLC increased its stake in ResMed by 1.1% in the 3rd quarter. Crestwood Advisors Group LLC now owns 212,264 shares of the medical equipment provider’s stock worth $16,336,000 after buying an additional 2,375 shares in the last quarter. Wealthsource Partners LLC increased its stake in ResMed by 17.8% in the 3rd quarter. Wealthsource Partners LLC now owns 7,150 shares of the medical equipment provider’s stock worth $550,000 after buying an additional 1,080 shares in the last quarter. Coastline Trust Co increased its stake in ResMed by 39.4% in the 3rd quarter. Coastline Trust Co now owns 14,615 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 4,130 shares in the last quarter. IFM Investors Pty Ltd purchased a new stake in ResMed in the 3rd quarter worth $341,000. Finally, California Public Employees Retirement System increased its stake in ResMed by 1.4% in the 3rd quarter. California Public Employees Retirement System now owns 299,798 shares of the medical equipment provider’s stock worth $23,072,000 after buying an additional 4,098 shares in the last quarter. Institutional investors and hedge funds own 60.38% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate ResMed Inc. (RMD) to Post $0.76 EPS” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/11/20/zacks-analysts-anticipate-resmed-inc-rmd-to-post-0-76-eps.html.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.